Silodosin

From WikiMD's Wellness Encyclopedia

What is Silodosin?[edit | edit source]

Silodosin
Silodosin Structural Formula V.1



What are the uses of this medicine?[edit | edit source]

Limitations of use:


How does this medicine work?[edit | edit source]

  • Silodosin is a selective antagonist of post-synaptic alpha-1 adrenoreceptors, which are located in the human prostate, bladder base, bladder neck, prostatic capsule, and prostatic urethra.
  • Blockade of these alpha-1 adrenoreceptors can cause smooth muscle in these tissues to relax, resulting in an improvement in urine flow and a reduction in BPH symptoms.


Who Should Not Use this medicine ?[edit | edit source]

This medicine cannot be used in patients with:


What drug interactions can this medicine cause?[edit | edit source]

  • Concomitant administration of strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ritonavir) and RAPAFLO is contraindicated.
  • RAPAFLO is not recommended in patients taking strong P-gp inhibitors such as cyclosporine.
  • RAPAFLO should not be used in combination with other alpha-blockers.
  • Concomitant administration of RAPAFLO and digoxin did not significantly alter the steady state pharmacokinetics of digoxin. No dose adjustment is required.
  • Concomitant use of PDE5 inhibitors with alpha-blockers including Rapaflo can potentially cause symptomatic hypotension.


Is this medicine FDA approved?[edit | edit source]

* The United States Food and Drug Administration and Health Canada approved silodosin under the brand name Rapaflo on 9 October 2008 and 11 January 2011, respectively.

How should this medicine be used?[edit | edit source]

Recommended dosage:

  • 8 mg capsules taken orally once daily with a meal.
  • 4 mg capsules taken orally once daily with a meal for those with moderate renal impairment.

Administration:

  • Patients should be instructed to take RAPAFLO once daily with a meal.


What are the dosage forms and brand names of this medicine?[edit | edit source]

This medicine is available in fallowing doasage form:

  • As Capsules: 8 mg and 4 mg

This medicine is available in fallowing brand namesː

  • RAPAFLO


What side effects can this medication cause?[edit | edit source]

The most common side effects of this medicine include:


What special precautions should I follow?[edit | edit source]

  • Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning RAPAFLO treatment. Patients should be cautioned about driving, operating machinery, or performing hazardous tasks when initiating therapy.
  • In patients with moderate renal impairment, RAPAFLO dose should be reduced to 4 mg once daily. Exercise caution and monitor such patients for adverse events. RAPAFLO is contraindicated in patients with severe renal impairment.
  • RAPAFLO should not be used in combination with other alpha-blockers.
  • Carcinoma of the prostate and BPH cause many of the same symptoms. These two diseases frequently co-exist. Examine patients thought to have BPH prior to starting therapy with RAPAFLO to rule out the presence of carcinoma of the prostate.
  • Inform patients planning cataract surgery to notify their ophthalmologist that they are taking RAPAFLO because of the possibility of Intraoperative Floppy Iris Syndrome (IFIS).
  • RAPAFLO has not been tested in patients with severe hepatic impairment, and therefore, should not be prescribed to such patients.


What to do in case of emergency/overdose?[edit | edit source]

Symptoms of overdosage may include:

Management of overdosage:

  • Restoration of blood pressure and normalization of heart rate may be accomplished by maintaining the patient in the supine position.
  • If this measure is inadequate, administration of intravenous fluid should be considered.
  • If necessary, vasopressors could be used, and renal function should be monitored and supported as needed.
  • Dialysis is unlikely to be of significant benefit since silodosin is highly (97%) protein bound.


Can this medicine be used in pregnancy?[edit | edit source]

  • Pregnancy Category B.
  • RAPAFLO is not indicated for use in women.


Can this medicine be used in children?[edit | edit source]

  • RAPAFLO is not indicated for use in pediatric patients.
  • Safety and effectiveness in pediatric patients have not been established.


What are the active and inactive ingredients in this medicine?[edit | edit source]

Active ingredient:

  • SILODOSIN

Inactive ingredients:

  • none


Who manufactures and distributes this medicine?[edit | edit source]

Manufactured by: Watson Laboratories, Inc. Corona, CA USA

Distributed by:


What should I know about storage and disposal of this medication?[edit | edit source]

  • Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).
  • Protect from light and moisture.


Silodosin Resources


Contributors: Deepika vegiraju